MCID: PHG002
MIFTS: 35

Phagocyte Bactericidal Dysfunction

Categories: Immune diseases

Aliases & Classifications for Phagocyte Bactericidal Dysfunction

MalaCards integrated aliases for Phagocyte Bactericidal Dysfunction:

Name: Phagocyte Bactericidal Dysfunction 12 44 15 73
Phagocytic Dysfunction 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3262
MeSH 44 D010585
UMLS 73 C0031306

Summaries for Phagocyte Bactericidal Dysfunction

Disease Ontology : 12 A primary immunodeficiency disease where phagocytes have a diminished ability to fight bacterial infection.

MalaCards based summary : Phagocyte Bactericidal Dysfunction, also known as phagocytic dysfunction, is related to chronic granulomatous disease and temporal arteritis. An important gene associated with Phagocyte Bactericidal Dysfunction is CYBB (Cytochrome B-245 Beta Chain), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and Integrin Pathway. The drugs Niacin and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells.

Wikipedia : 76 Phagocyte bactericidal dysfunction refers to a class of medical conditions where phagocytes have a... more...

Related Diseases for Phagocyte Bactericidal Dysfunction

Diseases related to Phagocyte Bactericidal Dysfunction via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 chronic granulomatous disease 28.7 CYBA CYBB MT-CYB NCF1 NCF2 NCF4
2 temporal arteritis 9.6
3 epidermodysplasia verruciformis 9.6
4 aging 9.6
5 pulmonary disease, chronic obstructive 9.6
6 kwashiorkor 9.6
7 retinitis pigmentosa 47 9.4 MT-CYB NCF1 NCF2
8 adrenal rest tumor 9.1 DUOX1 DUOX2
9 congenital hypothyroidism 8.9 DUOX1 DUOX2

Graphical network of the top 20 diseases related to Phagocyte Bactericidal Dysfunction:



Diseases related to Phagocyte Bactericidal Dysfunction

Symptoms & Phenotypes for Phagocyte Bactericidal Dysfunction

Drugs & Therapeutics for Phagocyte Bactericidal Dysfunction

Drugs for Phagocyte Bactericidal Dysfunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
2
Nicotinamide Approved, Investigational, Nutraceutical Phase 4 98-92-0 936
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
5 Interferon-gamma Phase 4,Phase 1
6 interferons Phase 4,Phase 1
7 Nicotinic Acids Phase 4
8 Vitamin B3 Nutraceutical Phase 4
9
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 22916-47-8 4189
10
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
12
Posaconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 171228-49-2 147912
13
alemtuzumab Approved, Investigational Phase 3,Phase 2,Early Phase 1,Not Applicable 216503-57-0
14 Antifungal Agents Phase 3,Phase 2,Not Applicable
15 Alkylating Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
16 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Immunosuppressive Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
18 Antiparasitic Agents Phase 3,Phase 2
19 Antiprotozoal Agents Phase 3,Phase 2
20 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2
21 Hormone Antagonists Phase 3,Phase 2,Not Applicable
22 Hormones Phase 3,Phase 2,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Not Applicable
24 Steroid Synthesis Inhibitors Phase 3,Phase 2
25
Fludarabine Approved Phase 1, Phase 2,Phase 2,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
26
Melphalan Approved Phase 2,Not Applicable 148-82-3 4053 460612
27
Methylprednisolone Approved, Vet_approved Phase 2,Not Applicable 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 2,Not Applicable 50-24-8 5755
29
Prednisone Approved, Vet_approved Phase 2,Not Applicable 53-03-2 5865
30
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
31
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
32
Mycophenolic acid Approved Phase 2,Phase 1,Not Applicable 24280-93-1 446541
33
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
34
Ibuprofen Approved Phase 2 15687-27-1 3672
35
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
36
Vidarabine Approved, Investigational Phase 2,Not Applicable 24356-66-9 32326 21704
37
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
38
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
39
Adalimumab Approved Phase 1, Phase 2 331731-18-1 16219006
40
Infliximab Approved Phase 1, Phase 2 170277-31-3
41
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
42 Cyclosporins Phase 2,Phase 1,Not Applicable
43 Antilymphocyte Serum Phase 2,Not Applicable
44 Antimetabolites Phase 2,Not Applicable
45 Antimetabolites, Antineoplastic Phase 2,Not Applicable
46 Antirheumatic Agents Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Calcineurin Inhibitors Phase 2,Not Applicable
48 Dermatologic Agents Phase 2,Phase 1,Not Applicable
49 Methylprednisolone acetate Phase 2,Not Applicable
50 Methylprednisolone Hemisuccinate Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Completed NCT00001317 Phase 4 interferon-gamma
2 Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease Terminated NCT01147042 Phase 4 IFN-gamma
3 Posaconazole to Treat Invasive Fungal Infections Completed NCT00033982 Phase 3 Posaconazole
4 Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care Completed NCT00023192 Phase 3 T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
5 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
6 Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD) Unknown status NCT01338675 Phase 1, Phase 2 Busulfan
7 Gene Therapy for Chronic Granulomatous Disease Unknown status NCT00564759 Phase 1, Phase 2 retroviral SF71-gp91phox transduced CD34+ cells
8 Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) in Children Completed NCT00927134 Phase 1, Phase 2
9 Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD) Completed NCT00799071 Phase 2 posaconazole (PSZ)
10 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Completed NCT01998633 Phase 2
11 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
12 Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease Completed NCT00001280 Phase 2 itraconazole
13 Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease Completed NCT00006417 Phase 2
14 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
15 Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients Recruiting NCT03547830 Phase 2 Plerixafor;Gcsf
16 Pioglitazone Therapy for Chronic Granulomatous Disease Recruiting NCT03080480 Phase 1, Phase 2 Pioglitazone
17 Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD Recruiting NCT03055247 Phase 2 Ibuprofen;Myelostim;Mozobil
18 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
19 Gene Therapy for X-linked Chronic Granulomatous Disease Recruiting NCT02757911 Phase 1, Phase 2
20 Gene Therapy for X-CGD Recruiting NCT01906541 Phase 1, Phase 2
21 Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD) Recruiting NCT01855685 Phase 1, Phase 2
22 Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
23 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
24 Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease Recruiting NCT02234934 Phase 1, Phase 2
25 Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome Active, not recruiting NCT02996448 Phase 2 NDV-3A
26 Gene Therapy for Chronic Granulomatous Disease in Korea Active, not recruiting NCT00778882 Phase 1, Phase 2 VM106
27 Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Active, not recruiting NCT00578643 Phase 2 Busulfan;Cyclophosphamide;Fludarabine;Cyclosporine
28 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
29 Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome Terminated NCT00527878 Phase 2 Ranitidine;Placebo
30 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
31 Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Terminated NCT00325078 Phase 1, Phase 2 Infliximab
32 Lentiviral Gene Therapy for X-Linked Chronic Granulomatous Disease (X-CGD) Withdrawn NCT01381003 Phase 1, Phase 2
33 Omalizumab to Treat Hyper-IgE (Job's) Syndrome Completed NCT00260702 Phase 1 Omalizumab (Xolair)
34 Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease Completed NCT00001765 Phase 1
35 Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up Completed NCT00001476 Phase 1 Gene Therapy Method for CGD
36 Diagnostic Effectiveness of Virtual Bronchoscopy Completed NCT00001515 Phase 1
37 Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease Recruiting NCT01851460 Phase 1
38 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
39 Effect of IFN-γ on Innate Immune Cells Active, not recruiting NCT02609932 Phase 1 Administration of drug (Interferon-gamma 1-b) subcutaneously
40 NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE Syndrome Unknown status NCT02228941
41 Chronic Granulomatous Disease Study in China Unknown status NCT02231996
42 Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders Unknown status NCT00006056 Not Applicable anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;etoposide;filgrastim;methotrexate
43 Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease Completed NCT02233036
44 Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related Disorders Completed NCT00005933
45 Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders Completed NCT00010361 Not Applicable cyclosporine;fludarabine;mycophenolate mofetil
46 Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer Recruiting NCT02108028
47 Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease Recruiting NCT03548818 Interferon Gamma-1B
48 High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease Recruiting NCT02629120 Early Phase 1 Campath;Busulfan;cyclophosphamide
49 Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 Recruiting NCT02116764
50 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies Recruiting NCT01652092 Not Applicable Alemtuzumab 0.3 mg;Cyclophosphamide;Busulfan;Fludarabine phosphate 40 mg;Melphalan;Alemtuzumab 0.2 mg;Busulfan;Fludarabine phosphate 30 mg;MESNA

Search NIH Clinical Center for Phagocyte Bactericidal Dysfunction

Cochrane evidence based reviews: phagocyte bactericidal dysfunction

Genetic Tests for Phagocyte Bactericidal Dysfunction

Anatomical Context for Phagocyte Bactericidal Dysfunction

MalaCards organs/tissues related to Phagocyte Bactericidal Dysfunction:

41
Bone Marrow, Bone, T Cells, Liver, Lung

Publications for Phagocyte Bactericidal Dysfunction

Articles related to Phagocyte Bactericidal Dysfunction:

# Title Authors Year
1
Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. ( 23908477 )
2013
2
Phagocyte dysfunction in polymyalgia rheumatica and other age-related, chronic, inflammatory conditions. ( 23904438 )
2013
3
Phagocytic dysfunction in epidermodysplasia verruciformis. ( 539961 )
1979
4
Phagocyte dysfunction in common variable immune deficiency. ( 895009 )
1977
5
Peripheral blood phagocyte dysfunction in children with kwashiorkor. ( 4604892 )
1974

Variations for Phagocyte Bactericidal Dysfunction

Expression for Phagocyte Bactericidal Dysfunction

Search GEO for disease gene expression data for Phagocyte Bactericidal Dysfunction.

Pathways for Phagocyte Bactericidal Dysfunction

Pathways related to Phagocyte Bactericidal Dysfunction according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.15 CYBA CYBB NCF1 NCF2 NCF4
2
Show member pathways
13.1 CYBA CYBB NCF1 NCF2 NCF4
3
Show member pathways
12.96 CYBB NCF1 NCF2 NCF4
4
Show member pathways
12.88 CYBA CYBB NCF1 NCF2 NCF4
5
Show member pathways
12.78 CYBA CYBB NCF1 NCF2 NCF4
6
Show member pathways
12.41 CYBA CYBB NCF1 NCF2 NCF4
7
Show member pathways
12.25 CYBA CYBB NCF1 NCF2 NCF4
8
Show member pathways
12.21 CYBA CYBB NCF1 NCF2 NCF4
9
Show member pathways
12.15 CYBA CYBB NCF1 NCF2
10
Show member pathways
12.09 CYBA CYBB NCF1 NCF2
11
Show member pathways
11.99 CYBA CYBB NCF1 NCF2 NCF4
12 11.87 CYBA NCF1 NCF2
13 11.87 CYBA NCF1 NCF2 NCF4
14 11.84 CYBA CYBB NCF1 NCF2 NCF4
15
Show member pathways
11.52 CYBA CYBB NCF1 NCF2 NCF4
16
Show member pathways
11.19 DUOX1 DUOX2
17 11.16 CYBA CYBB NCF1 NCF2
18
Show member pathways
11.09 CYBA CYBB NCF1 NCF2 NCF4
19 10.94 CYBA NCF4
20 10.14 CYBA CYBB NCF1 NCF2 NCF4

GO Terms for Phagocyte Bactericidal Dysfunction

Cellular components related to Phagocyte Bactericidal Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.61 CYBA CYBB NCF1
2 specific granule membrane GO:0035579 9.46 CYBA CYBB
3 neuronal cell body GO:0043025 9.43 CYBA CYBB NCF1
4 tertiary granule membrane GO:0070821 9.4 CYBA CYBB
5 phagocytic vesicle membrane GO:0030670 9.37 CYBA CYBB
6 apical plasma membrane GO:0016324 9.33 CYBA DUOX1 DUOX2
7 rough endoplasmic reticulum GO:0005791 9.32 CYBB NCF1
8 phagolysosome GO:0032010 9.13 NCF1 NCF2 NCF4
9 NADPH oxidase complex GO:0043020 9.02 CYBA CYBB NCF1 NCF2 NCF4

Biological processes related to Phagocyte Bactericidal Dysfunction according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.86 CYBA CYBB NCF1 NCF2
2 cellular response to oxidative stress GO:0034599 9.83 CYBA CYBB NCF1 NCF2 NCF4
3 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.8 CYBA CYBB NCF1 NCF2 NCF4
4 electron transport chain GO:0022900 9.78 CYBA CYBB NCF1 NCF2
5 response to drug GO:0042493 9.77 CYBA CYBB MT-CYB
6 cell redox homeostasis GO:0045454 9.77 CYBA CYBB NCF1 NCF2 NCF4
7 superoxide metabolic process GO:0006801 9.76 CYBA CYBB NCF1 NCF2
8 oxidation-reduction process GO:0055114 9.76 CYBA CYBB DUOX1 DUOX2 MT-CYB NCF1
9 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.72 CYBA CYBB NCF1 NCF2 NCF4
10 positive regulation of catalytic activity GO:0043085 9.63 NCF2 NCF4
11 response to nutrient GO:0007584 9.62 CYBB MT-CYB
12 cellular oxidant detoxification GO:0098869 9.62 DUOX1 DUOX2
13 phagocytosis GO:0006909 9.61 NCF2 NCF4
14 cellular defense response GO:0006968 9.61 NCF1 NCF2
15 response to cAMP GO:0051591 9.59 DUOX1 DUOX2
16 cellular response to cadmium ion GO:0071276 9.58 CYBB NCF1
17 reactive oxygen species metabolic process GO:0072593 9.58 CYBA DUOX1
18 hydrogen peroxide catabolic process GO:0042744 9.57 DUOX1 DUOX2
19 hydrogen peroxide biosynthetic process GO:0050665 9.56 CYBA CYBB DUOX1 DUOX2
20 thyroid hormone generation GO:0006590 9.55 DUOX1 DUOX2
21 hormone biosynthetic process GO:0042446 9.54 DUOX1 DUOX2
22 response to aldosterone GO:1904044 9.52 CYBA CYBB
23 cellular response to L-glutamine GO:1904845 9.51 CYBA CYBB
24 cuticle development GO:0042335 9.49 DUOX1 DUOX2
25 respiratory burst GO:0045730 9.35 CYBA CYBB NCF1 NCF2 NCF4
26 superoxide anion generation GO:0042554 9.02 CYBA CYBB DUOX1 NCF1 NCF2

Molecular functions related to Phagocyte Bactericidal Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.72 CYBA CYBB DUOX1 DUOX2 MT-CYB
2 heme binding GO:0020037 9.56 CYBA CYBB DUOX1 DUOX2
3 peroxidase activity GO:0004601 9.4 DUOX1 DUOX2
4 NAD(P)H oxidase activity GO:0016174 9.37 DUOX1 DUOX2
5 electron transfer activity GO:0009055 9.35 CYBA CYBB MT-CYB NCF1 NCF2
6 superoxide-generating NADPH oxidase activator activity GO:0016176 9.33 NCF1 NCF2 NCF4
7 superoxide-generating NADPH oxidase activity GO:0016175 8.92 CYBA CYBB NCF1 NCF2

Sources for Phagocyte Bactericidal Dysfunction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....